• IMA sites
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Wed, 29.05.24

Instructions for Authors

All manuscripts must be according to the JIMM editorial policies. The JIMM accepts manuscripts in Hebrew or in English related to military medicine. This includes but is not necessarily limited to health issues of armed forces, physiology, trauma and battle injuries, military psychiatry/psychology, emergency medicine, CBRN (chemical, biological, radiological, nuclear) medicine, medical administration including mass casualty readiness and response, occupational and environmental medicine (climate injuries and tolerance, altitude and diving medicine) and training and exercise in military medicine.

Submissions must include:

  1. The main manuscript in a single MS WORD document with tables and figures embedded after the references (if permitted).
  2. A Cover letter to the editor, including a sentence on the type of manuscript and its content and for manuscripts with more than 6 authors, the contributions of all the authors.
  3. The JIMM Submission Form, signed by all authors regarding copyright transmittal, disclosure of potential conflicts of interest and other relevant disclosures.
  4. A copy of IRB approval or Animal Welfare and Ethical Review Body as relevant. If the study was performed in the IDF, a copy of the IDF IRB approval must be submitted.

Manuscript submission shall be by email, to [email protected].

Manuscripts may be of the following types:

  1. Report on original research
  2. Original clinical observations accompanied by analysis and discussion
  3. Letter to the Editor
  4. Critical review
  5. Case report with discussion
  6. Conference summary
  7. Clinical guideline / opinion article

Report on original research
An original research article details results of a study not previously published. It must include a structured abstract in English (no more than 250 words, background, methods, results  and conclusions), also, if the article was written in Hebrew then it should also include an abstarct in Hebrew. The main article (sectioned: introduction, methods, results, discussion) may be no more than 4,000 words. Up to 20 references are permitted. A total of 4 tables and figures are permitted. Up to 6 authors are permitted, but in exceptional cases, the editor may allow more, based on the contribution of all authors as detailed in the cover letter.

Original clinical observations accompanied by analysis and discussion
This might be a prospective or retrospective case series. Its structure and other details are identical to an original research article as stated above.

Letter to the Editor
A letter to the Editor is a communication to the editor usually relating to an article previously published in the JIMM, but not necessarily. Up to 2 authors are permitted. It has no abstract tables or figures, is up to 750 words and may include up to 3 references.

Critical review
A critical review article summarizes the data available on a specific topic. It includes a non-structured abstract in English (150 - 250 words, and if it was written in Hebrew it should also include an abstarct in Hebrew). the main article, up to 4,000 words structured as relevant, and up to 40 references. A total of 4 tables and figures are permitted. Up to 3 authors are permitted.

Case report with discussion
A case report details the history, clinical presentation, workup, and outcome of a patient or disease relevant to the JIMM. There must be a discussion of the finding reported. Up to 3 authors are permitted. It includes an abstract in English (150 - 250 words, and if the report was written in Hebrew it should also include an abstarct in Hebrew). is up to 1,500 words and may include up to 5 references. A total of 3 tables and figures are permitted. If the case report is based on an image, it may appear under the JIMMAGE category.

Conference summary
A conference summary details any aspect of a relevant conference that the author took part in. Up to 2 authors are permitted. 1 table or figure is permitted. It has no abstract, is up to 2,000 words and may include up to 10 references.

Clinical guideline / opinion article
A clinical guideline details the approach to management of clinical condition or an opinion on a contemporary issue related to military medicine. Up to 3 authors are permitted. It has no abstract, is up to 4,000 words and may include up to 4 tables and graphs and 30 references.

Preparing your manuscript
The manuscript must be prepared in MS-WORD format, double spaced throughout, Hebrew in DAVID font and English in Times New Roman, both 12 points. Place the title page, abstract, tables and figures on separate pages, and the rest of the text without page breaks. Pages and line should be numbered (line numbering continuous).

  • Abbreviations: Use only standard abbreviations; use of nonstandard abbreviations can be confusing to readers. Avoid abbreviations in the title of the manuscript. The spelled-out abbreviation followed by the abbreviation in parenthesis should be used on first mention unless the abbreviation is a standard unit of measurement.
  • Units: Please use SI units.
  • Language: Manuscripts must be submitted in Hebrew or in English. The level of the general and scientific Hebrew or English must be appropriate for the JIMM otherwise the manuscript will be returned to the authors for copyediting. Manuscripts translated from another language with automatic translators such as google translate are not acceptable.
  • Medications: Always present generic names. If there is particular importance to present a proprietary name, add it in brackets with the name, city and state of the manufacturer.
  • Tables: Tables should be numbered and cited in the text in sequence using Arabic numerals (i.e. Table 1, Table 2 etc.). Tables may not be larger than one A4 page in length and should be placed at the end of the document text file. Color and shading may be used, but markings should be adequate for differentiating the various aspects even if the final format is in black and white. Parts of the table can be highlighted using superscript, numbering, lettering, symbols or bold text, the meaning of which should be explained in a table legend. Commas should not be used to indicate numerical values.
  • Figures: Figures should be numbered and cited in the text in sequence using Arabic numerals (i.e. Figure 1, Figure 2 etc.). Figures should be closely cropped to minimize the amount of white space surrounding the illustration. Cropping figures improves accuracy when placing the figure in combination with other elements when the accepted manuscript is prepared for publication on our site. Individual figure files should not exceed 10 MB.

    Embed tables and figures at the end of the manuscript (after the references) each on a separate page. Following each table or figure include a clear legend starting with the table/figure title (max 15 words) and on a separate line the legends (max 300 words). Do not include the legend in a graphic file. The purpose of the legend is to enable the table or figure to be understood when standing alone. Designate where the table or figure should be in the manuscript using the less/more than signs on a separate line:
    <Please place Table 1 here>
    <Please place Figure 3 here>

    Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures (or tables) that have previously been published elsewhere.

Title page

  • Article title. The title provides a distilled description of the complete article and should include information that, along with the abstract, will make electronic retrieval of the article sensitive and specific.
  • Author information. Report one given name, initials for other names followed by the surname. Report each author's highest academic degrees. For active military personnel and for reserve officers with ranks of LTC and above, report the abbreviated rank. By means of superscript numbering, on a line below the authors’ names, indicate the affiliations (name(s) of the department(s) and institution(s) or organization(s)) where the work should be attributed. On a separate line, name the contact person with full contact details.
  • Disclaimers: A statement that the views expressed in the submitted article are the author's own and not an official position of the institution, funder, the IDF or the IMA.
  • Source(s) of support. These include grants, equipment, drugs, and/or other support that facilitated conduct of the work described in the article or the writing of the article itself.
  • Word count. State word counts for the abstract and the main text (excluding the abstract, acknowledgments, tables, figure legends, and references). This allows editors and reviewers to assess whether the information contained in the paper warrants the paper's length, and whether the submitted manuscript fits within the journal's formats and word limits.
  • Number of tables.
  • Number of figures.

Main manuscript text

  • Abstract. For manuscript with abstracts. the abstract must be submitted in English, 150 to 250 words. For articles submitted in Hebrew, abstracts in both Hebrew and English must be submitted. Abstracts for original research must be structured: background, methods, results, conclusions, and abstracts for other manuscript types structured as relevant.
  • Introduction. Provide a context or background for the study (that is, the nature of the problem and its significance). State the specific purpose or research objective of, or hypothesis tested by, the study or observation. Cite only directly pertinent references, and do not include data or conclusions from the work being reported. Do not try to make a complete review of the topic. Try to keep the introduction short and focused. 350 words should be sufficient. End the introduction with a brief description of the purpose of the study.
  • Methods. The guiding principle of the Methods section should be clarity about how and why a study was done in a particular way. The Methods section should aim to be sufficiently detailed such that others with access to the data would be able to reproduce the results. In general, the section should include only information that was available at the time the plan or protocol for the study was being written; all information obtained during the study belongs to the Results section. The Methods section should include a statement indicating that the research was approved by an independent local, regional or national review body (e.g., ethics committee, institutional review board).

    Selection and Description of Participants: Clearly describe the selection of observational or experimental participants (healthy individuals or patients, including controls), including eligibility and exclusion criteria and a description of the source population. Because the relevance of such variables as age, sex, or ethnicity is not always known at the time of study design, researchers should aim for inclusion of representative populations into all study types and at a minimum provide descriptive data for these and other relevant demographic variables.

    Ensure correct use of the terms sex (when reporting biological factors) and gender (identity, psychosocial or cultural factors), and, unless inappropriate, report the sex and/or gender of study participants. If the study was done involving an exclusive population, for example in only one sex, authors should justify why, except in obvious cases, (e.g., prostate cancer).” Authors should define how they determined race or ethnicity and justify their relevance. Authors should use neutral, precise, and respectful language to describe study participants and avoid the use of terminology that might stigmatize participants.

    Technical Information: Specify the study's main and secondary objectives–usually identified as primary and secondary outcomes. Identify methods, equipment (give the manufacturer's name and address in parentheses), and procedures in sufficient detail to allow others to reproduce the results. Give references to established methods, including statistical methods (see below); provide references and brief descriptions for methods that have been published but are not well-known; describe new or substantially modified methods, give the reasons for using them, and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. Identify appropriate scientific names and gene names.

    Statistics: Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to judge its appropriateness for the study and to verify the reported results. When possible, quantify findings and present them with appropriate indicators of measurement error or uncertainty (such as confidence intervals). Avoid relying solely on statistical hypothesis testing, such as P values, which fail to convey important information about effect size and precision of estimates. The statement that "no significant difference was found between two groups" cannot be made unless a power study was done and is reported with all the values (expected significant difference, alpha and beta). A large number of patients (at least 60, and often more, in each group or subgroup) is required to make such a statement. If no such power study was done, the author must state: "With the numbers available, no significant difference could be detected."

    Ninety-five percent confidence intervals are required whenever the results of survivorship analysis are given in the text or in graphs. Authors are encouraged to use 95% confidence intervals in addition to or instead of standard deviations when reporting results. Use of the word "correlation" requires reporting of the Pearson product-moment correlation coefficient r.
  • Results. Present your results in logical sequence in the text, tables, and figures, giving the main or most important findings first. Do not repeat the data in the tables or figures in the text; emphasize or summarize only the most important observations. Provide data on all primary and secondary outcomes identified in the methods section. Extra or supplementary materials and technical details can be placed in a supplementary file where they will be accessible but will not interrupt the flow of the text.

    Give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated. Restrict tables and figures to those needed to explain the argument of the paper and to assess supporting data. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables. Separate reporting of data by demographic variables, such as age and sex, facilitate pooling of data for subgroups across studies and should be routine, unless there are compelling reasons not to stratify reporting, which should be explained.
  • Discussion. Begin the discussion by briefly summarizing the main findings, and explore possible mechanisms or explanations for these findings. Emphasize the new and important aspects of your study and put your findings in the context of what was known before this study. State the limitations of your study, and explore the implications of your findings for future research and for clinical practice or policy.

    Link the conclusions with the goals of the study but avoid unqualified statements and conclusions not adequately supported by the data. In particular, distinguish between clinical and statistical significance, and avoid making statements on economic benefits and costs unless the manuscript includes the appropriate economic data and analyses. Avoid claiming priority or alluding to work that has not been completed.

References are limited to 20 in original research articles, 40 in review articles, 5 in case reports, 3 in letters to the Editor and 30 in clinical guidelines.
Only articles, clinical trial registration records and abstracts that have been published or are in press, or are available through public e-print/preprint servers, may be cited.
Unpublished abstracts, unpublished data and personal communications should not be included in the reference list, but may be included in the text and referred to as "unpublished observations" or "personal communications" giving the names of the involved researchers. Obtaining permission to quote personal communications and unpublished data from the cited colleagues is the responsibility of the author. Only footnotes are permitted.
For references with up to 4 authors, name all authors. If there are more than 4, name the first 3 followed by et al. Quote surname followed by a space and initials of given names without spaces, dots or commas. Follow each author by a comma and space except before “et al”. Quote the title of the reference with small letters (except the first word) followed by a full stop. Use Journal abbreviations according to Index Medicus/MEDLINE, followed immediately by year of publication, semicolon; space, volume, (please quote issue in brackets, as it helps finding the article on journal websites) and give page numbers without abbreviating end page number, followed by a full stop.


  1. Martin JW, Christopher GW, Eitzen EM. History of biological weapons: From poisoned darts to intentional epidemics. In: Dembek ZF, ed. Medical aspects of biological warfare. Washington, DC: Office of the Surgeon General, US Army Medical Department Center and School; Borden Institute, Walter Reed Army Medical Center; 2007:1-20.
  2. Perkins MW, Pierre Z, Rezk P et al. Acute respiratory toxicity following inhalation exposure to soman in guinea pigs. Toxicol Appl Pharmacol 2010; 245(2):171-178.
  3. Wright BS, Rezk PE, Graham JR et al. Acute lung Injury following Inhalation exposure to nerve agent VX in guinea pigs. Inhal Toxicol 2006; 18(6):448-437.
  4. עדיני ב', לאור ד', כהן ר' וחב'. חמשת הדיברות להיערכות מערכת הבריאות בישראל לשעת חירום. הרפואה 2010; כרך 147(7):445-450.

Any in press articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available if requested by the editorial office.
If you used a reference manager such as Endnote® or Mendeley® do not submit in the reference manager format but extract to unformatted text.

Supplementary files
As the length of data is restricted, authors can upload supplementary files such as additional text, anonymized datasets, tables, movies, or other information as necessary to available public recognized repositories, as long as the repository guarantees keeping the data at the given location for at least 10 years, without the possibility of changing it. The data must be uploaded to the repository prior to submission to the JIMM and the URL stated in the submission so the reviewers may see it as necessary. The JIMM will publish the URL.
Do not include files such as patient consent forms, certificates of language editing, or revised versions of the main manuscript document with tracked changes.
Results that would otherwise be indicated as "data not shown" should be included as additional files. Since many web links and URLs rapidly become broken, the JIMM requires that supporting data are included as additional files, or deposited in a recognized repository. Please do not link to data on a personal/departmental website. Do not include any individual participant details. The maximum file size for additional files is 10 MB each. Each additional file should be cited in sequence within the main body of text.
If additional material is provided, please list the following information in a separate section of the manuscript text before the references:

  1. File name (e.g. Additional file 1).
  2. File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including name and a URL of an appropriate viewer if format is unusual).
  3. Title of data.
  4. Description of data.

System details:
Journal of Israeli Military Medicine (JIMM)
Katznelson Street No. 1, Kiryat Ono, Zip Code 5529801
Phone: 0723398272
Email Address: [email protected]
Website URL: https://www.ima.org.il/MedicineArmy/Default.aspx

Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel